Erius (desloratadine) coated tablets 5 mg. №10


Manufacturer: Belgium

To eliminate symptoms associated with allergic rhinitis, such as sneezing, nasal discharge, itching, swelling and nasal congestion, as well as itchy and red eyes, watery eyes, itchy palate, and cough. To eliminate symptoms associated with urticaria, such as itching and rashes.



Erius Composition
active substance: desloratadine, 1 tablet contains 5 mg of desloratadine.

excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, corn starch, talc, carnauba wax, white wax.

film shell: lactose; hydroxypropyl methylcellulose; titanium dioxide (E 171) polyethylene glycol; indigo (E 132).

transparent shell: hypromellose, polyethylene glycol.

Erius Dosage form
Film-coated tablets.

Basic physical and chemical properties: round tablets, light blue, embossed in the form of elongated letters “S” and “P” on one side and smooth on the other side.

Pharmacotherapeutic group
Antihistamines for systemic use. ATX code R06A X27.

Desloratadine is a long-acting non-sedating antihistamine that selectively antagonizes peripheral H1 receptors. After oral administration, desloratadine selectively blocks peripheral histamine H1 receptors.

In in vitro studies, desloratadine has demonstrated its anti-allergic and anti-inflammatory properties on endothelial cells. This was manifested by inhibition of the release of proinflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human mast cells / basophils, as well as inhibition of the expression of adhesion molecules such as P-selectin. The clinical significance of these observations still needs confirmation.

In high-dose clinical studies in which desloratadine was administered daily at a dose of up to 20 mg for 14 days, statistically significant changes in the cardiovascular system were not observed. In a clinical pharmacological study, when using 45 mg per day (10 times the maximum daily clinical dose) for 10 days, no prolongation of the QT interval was observed.

In patients with allergic rhinitis, Erius effectively eliminated symptoms such as sneezing, nasal discharge and itching, as well as eye irritation, watery eyes and redness, and itchy palate. Erius effectively controlled symptoms for 24 hours.

Desloratadine hardly penetrates the central nervous system. In controlled clinical trials, when taken at the recommended dose of 5 mg per day, the incidence of drowsiness did not differ from the placebo group. In clinical studies, a single dose of Erius in a daily dose of 7.5 mg did not affect psychomotor activity.

Erius Pharmacokinetics

Plasma concentrations of desloratadine can be determined 30 minutes after taking the drug. Desloratadine is well absorbed, the maximum concentration is reached after 3 hours; the half-life is about 27 hours. The degree of cumulation of desloratadine corresponded to its half-life (approximately 27 hours) to the frequency of taking 1 time per day. The bioavailability of desloratadine was dose proportional, ranging from 5 to 20 mg.

In a pharmacokinetic study in which patient demographics were comparable to the general population with seasonal allergic rhinitis, 4% of the participants had a high concentration of desloratadine. This amount may vary depending on ethnicity. The maximum concentration of desloratadine was about 3 times higher after about 7 hours, the terminal half-life is about 89 hours. The safety profile of these patients did not differ from that in the general population.


Hypersensitivity to the active substance or to any auxiliary or to loratadine.